

## Press Release

March 28, 2013

For Immediate Release

Contact: Doranelly Koltchev Ph.D.

[dkoltchev@biopharmaresearchcouncil.org](mailto:dkoltchev@biopharmaresearchcouncil.org)

732.403.3131

### **Biopharmaceuticals: Challenges, Innovation, and Competition**

A BioPharma Research Council Program

**April 9, 2013, Chemical Heritage Foundation, Philadelphia**

(Tinton Falls,, NJ) The BioPharma Research Council (BRC) will present two co-located conferences on Tuesday, April 9, 2013 at the Chemical Heritage Foundation in Philadelphia.

**Current Trends in Biosimilars Development and Regulatory Pathways in the Global Marketplace** will address topics ranging from the global regulatory landscape for biosimilars and biobetters to legal considerations, business perspectives, recent scientific breakthroughs, services market (CRO, CMO, clinical trials), and uptake from patient perspectives.

**Advancements in Nucleic Acid Therapeutics: From Concept to Clinical Practice** will focus on current advancements in developing nucleic acid therapeutics from discovery to understanding their mechanisms of action to clinical application in diverse therapeutic areas. Presentations by key thought leaders will highlight the progress, evaluate the challenges, and discuss the future direction of cutting edge technologies in nucleic acid therapeutics (including gene therapy) to alleviate human disease.

The programs will be of greatest interest to academic and commercial pharmaceutical researchers and drug developers, as well as medical professionals.

Dr. Dolly Koltchev, Program Director of the BioPharma Research Council, has developed these programs in response to the ongoing paradigm shift from blockbuster drugs to targeted approaches that have changed the drug discovery and development landscape.

"In recent years, biopharmaceuticals have become the fastest growing segment of the global healthcare development market," says Dr. Koltchev. "Patent expirations and demand for top-selling biologics brands in key therapeutic areas like cancer, diabetes, and autoimmune diseases have opened new opportunities for developing cost effective follow-on biologics (biosimilars).

"Alternatively", she says, "nucleic acid therapeutics have been established in the pipelines and studied in clinical trials. Development of new technologies, delivery systems and the opportunity to cure human diseases have paved the way to potential commercialization of nucleic acid therapeutics including gene therapy.

"For all these reasons, it's an important time to take a look at the current state of the science and trends in the biopharmaceutical industry."

For more information and registration, please visit [www.biopharmaresearchforum.org](http://www.biopharmaresearchforum.org) or call Joanne Gere, Executive Director, at 732-403-3137.

-----###-----

The BioPharma Research Council (BRC) is a nonprofit producer of high-content programs for the biopharmaceutical research community. We promote partnerships across industry, academia, government, and supplier groups, by providing scientific

meetings, opportunities for committee work, speaking, networking, and professional growth. [www.biopharmaresearchcouncil.org](http://www.biopharmaresearchcouncil.org)

**BioPharma Research Council . 1 Sheila Drive, Tinton Falls, NJ, USA 07724**